Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT03067467
Status
Recruiting
Apply to this trial

Conditions

  • Brain Tumor Adult

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Hyperpolarized 13C-Pyruvate — DRUG
    Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.
  • Gadolinium — DRUG
    Brain MRI performed with and without gadolinium-based contrast.

Study Details

This is a non-randomized, purely observational, feasibility study to detect metabolic changes in patients with brain malignancy using a novel hyperpolarized \[1-13C\]pyruvate MRSI.

Key Dates

Start date
Jun 1, 2019
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
25 participants (estimated)

Arms

  • Arm: Brain Tumor Patients
    Brain Tumor patients will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI.

Primary Outcome Measure

13C-pyruvate Metabolic Product Ratio [ Time Frame: Screening (Baseline) and 1 day of Study Visit ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UT Southwestern Medical CenterDallasTexas75390
Jae Mo Park, PhD

Find similar trials in Dallas, TX

By research site
UT Southwestern Medical Center· Dallas, TX

Related Studies